Great Valley Advisor Group Inc. Has $465,000 Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Great Valley Advisor Group Inc. lifted its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 5.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 442 shares of the biopharmaceutical company’s stock after purchasing an additional 21 shares during the quarter. Great Valley Advisor Group Inc.’s holdings in Regeneron Pharmaceuticals were worth $465,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of the business. Quent Capital LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 5.1% in the first quarter. Quent Capital LLC now owns 390 shares of the biopharmaceutical company’s stock valued at $375,000 after buying an additional 19 shares during the period. Tidal Investments LLC boosted its stake in Regeneron Pharmaceuticals by 16.8% in the 1st quarter. Tidal Investments LLC now owns 4,955 shares of the biopharmaceutical company’s stock worth $4,774,000 after purchasing an additional 711 shares during the period. Plato Investment Management Ltd increased its holdings in Regeneron Pharmaceuticals by 1,846.3% during the 1st quarter. Plato Investment Management Ltd now owns 2,394 shares of the biopharmaceutical company’s stock worth $2,304,000 after purchasing an additional 2,271 shares in the last quarter. Swedbank AB acquired a new stake in shares of Regeneron Pharmaceuticals in the 1st quarter valued at about $129,257,000. Finally, Atria Investments Inc grew its holdings in shares of Regeneron Pharmaceuticals by 12.2% during the first quarter. Atria Investments Inc now owns 8,657 shares of the biopharmaceutical company’s stock worth $8,317,000 after buying an additional 941 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock opened at $753.03 on Wednesday. The company has a market capitalization of $82.75 billion, a price-to-earnings ratio of 18.63, a PEG ratio of 2.84 and a beta of 0.15. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. Regeneron Pharmaceuticals, Inc. has a 52 week low of $735.95 and a 52 week high of $1,211.20. The company has a 50-day simple moving average of $929.13 and a 200 day simple moving average of $1,024.43.

Analyst Ratings Changes

REGN has been the subject of a number of recent research reports. Evercore ISI reduced their price target on Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating for the company in a research report on Thursday, October 24th. Leerink Partnrs downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 24th. StockNews.com cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 4th. JPMorgan Chase & Co. decreased their price objective on Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating for the company in a report on Thursday, October 24th. Finally, Truist Financial dropped their target price on Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a “buy” rating on the stock in a report on Friday, November 1st. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $1,099.55.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.